Hepatitis C medication costs between roughly $22,000 and $95,000 at list price for a full treatment course, depending on which drug your doctor prescribes and how long you need to take it. The good news: most people pay far less than that. With insurance, manufacturer assistance programs, or authorized generics, out-of-pocket costs can drop to a few hundred dollars or even zero.
List Prices for Major Hep C Drugs
Three direct-acting antiviral medications dominate hepatitis C treatment today. Each one cures the infection in the vast majority of people, but their sticker prices vary significantly.
Mavyret, made by AbbVie, has a list price of $26,400 for the standard 8-week course. Some patients need 12 weeks of treatment, which raises the cost to $39,600, and a 16-week course runs $52,800. Epclusa and Harvoni, both made by Gilead Sciences, carry list prices between $22,000 and $36,000 per treatment course depending on the pharmacy and any negotiated discounts. Sovaldi, an older Gilead drug, originally launched at $84,000 for a 12-week course and helped spark the national debate over hepatitis C drug pricing, though it’s less commonly prescribed now.
These are wholesale acquisition costs, essentially the price before any rebates, discounts, or insurance negotiations. Almost nobody pays the full list price out of pocket.
What You’ll Actually Pay With Insurance
Your real cost depends entirely on what kind of coverage you have and which drug your plan prefers.
Private insurance plans typically place hepatitis C drugs on their specialty tier, which means a percentage-based copay rather than a flat fee. That percentage can translate to thousands of dollars before you hit your plan’s out-of-pocket maximum. However, many plans negotiate substantial rebates from manufacturers, and some cover the entire cost after a manageable copay.
Under Medicare Part D, beneficiaries without additional financial assistance paid an average of $2,200 more out of pocket when their plan steered them toward a higher-cost brand-name drug instead of a lower-cost alternative. Medicare’s own spending jumped by over $8,000 per beneficiary in those cases. The lesson: which specific drug your Part D plan covers on its formulary makes a real difference in your costs. Starting in 2025, Medicare’s $2,000 annual out-of-pocket cap on prescription drugs limits the maximum any Part D enrollee will spend, which is a significant change for hepatitis C patients.
Medicaid covers hepatitis C treatment in every state, but access varies. Some state Medicaid programs have historically restricted coverage to patients whose liver damage has progressed to advanced fibrosis or cirrhosis. Others have required a period of sobriety from drugs or alcohol before approving treatment. These restrictions have been loosening under federal pressure, but they still exist in certain states. If your Medicaid application is denied, it’s worth appealing or asking your provider to submit a prior authorization with documentation of your diagnosis.
Authorized Generics Can Cut Costs Significantly
Gilead Sciences has authorized generic versions of both Epclusa and Harvoni. These are chemically identical to the brand-name drugs but sold at a lower price point. Despite their availability, a federal Inspector General report found that many Part D plans continued steering patients toward the more expensive brand-name versions, costing both Medicare and patients more money.
If your doctor prescribes Epclusa or Harvoni, ask your pharmacist or insurance plan whether the authorized generic is available on your formulary. Switching could save you thousands of dollars with no difference in effectiveness or safety.
Patient Assistance and Copay Programs
Both major manufacturers run assistance programs for people who can’t afford their medications. AbbVie offers patient assistance for Mavyret through its myAbbVie Assist program, which provides the drug at no cost to qualifying patients. Eligibility is based on income and insurance status. Gilead runs a similar program called Support Path for Epclusa and Harvoni.
If you have insurance but your copay is still too high, nonprofit foundations sometimes offer grants to cover the gap. The PAN Foundation runs a hepatitis C copay assistance fund, though it opens and closes depending on available funding. When the fund is closed, you can join a waitlist or sign up for FundFinder, a free alert service that monitors over 200 patient assistance funds across nine charitable organizations and notifies you when one opens.
Other organizations worth checking include the HealthWell Foundation and the Patient Access Network. Availability shifts frequently, so checking multiple sources at the time you need treatment gives you the best chance of finding help.
Why Treatment Length Affects Your Bill
Most people with hepatitis C who haven’t been treated before need 8 to 12 weeks of medication. The specific duration depends on which genotype of the virus you have, whether you have cirrhosis, and whether you’ve tried treatment in the past.
With Mavyret, the jump from 8 weeks to 12 weeks adds $13,200 to the list price. A 16-week course costs double the 8-week course. Your doctor determines the right duration based on your specific situation, but understanding this helps you anticipate costs and plan your insurance or assistance strategy. If you’re comparing options with your provider, the total treatment cost (not just the per-pill price) is the number that matters.
Practical Steps to Lower Your Cost
- Ask about generics first. Authorized generics of Epclusa and Harvoni are identical to the originals and often cheaper through insurance.
- Check your formulary. Your insurance plan’s preferred hepatitis C drug will almost always cost you less than a non-preferred one. Ask your doctor if switching is an option.
- Apply to manufacturer programs early. Both AbbVie and Gilead offer assistance, but approval takes time. Start the application before you fill your first prescription.
- Use FundFinder. Sign up for alerts from the PAN Foundation and similar organizations so you’re notified the moment copay assistance becomes available.
- Appeal Medicaid restrictions. If your state Medicaid program denies coverage based on fibrosis stage or sobriety requirements, your provider can often get the decision reversed with additional documentation.